Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004216 · ClinicalTrials.gov registry record · Phase 1
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
A Phase 1 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00004216 is a Phase 1 study that has completed, run by Vion Pharmaceuticals.
The verdict
NCT00004216, a Phase 1 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have advanced or metastatic solid tumors that have not responded to previous therapy.
Interventions
- DRUG trimethoprim-sulfamethoxazole
- DRUG ciprofloxacin
- BIOLOGICAL salmonella VNP20009
- DRUG cefixime
- DRUG ceftriaxone sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004216
The ClinicalTrials.gov registry entry for NCT00004216 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Vion Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which trimethoprim-sulfamethoxazole is the first listed.
NCT00004216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004216 about?
NCT00004216 is a clinical study titled "VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy". RATIONALE: Biological therapies such as VNP20009 use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of VNP20009 in treating patients who have advanced or metastatic solid tumors that have not responded to previous ...
What is the current status of trial NCT00004216?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-08. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00004216?
The interventions under investigation include: trimethoprim-sulfamethoxazole (DRUG), ciprofloxacin (DRUG), salmonella VNP20009 (BIOLOGICAL), cefixime (DRUG), ceftriaxone sodium (DRUG).
Who is sponsoring clinical trial NCT00004216?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.